An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are:
- To demonstrate the efficacy of once daily administration of Nasacort AQ 110 µg compared
with placebo in children 2-5 years of age with perennial allergic rhinitis; and
- To assess the safety of Nasacort AQ 110 µg in children 2-5 years of age.